Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12817939 | 0.84 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 | |
| SCHEMBL9625632 | 0.81 | ALDH1A1 (0.46) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL31666926 | 0.80 | RPS6KA2 (0.42) | CYP1A2CYP2C9CYP2C19ALDH1A1RPS6KA2 | |
| SCHEMBL3289588 | 0.78 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 | |
| SCHEMBL5591074 | 0.78 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 | |
| SCHEMBL17789326 | 0.78 | ALDH1A1 (0.47) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 | |
| SCHEMBL799702 | 0.78 | DRD3 (0.45) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 | |
| SCHEMBL8275914 | 0.78 | HTR1A (0.46) | ALDH1A1DRD3 | |
| SCHEMBL5405619 | 0.77 | USP19 (0.41) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 | |
| SCHEMBL14909935 | 0.77 | ALDH1A1 (0.44) | CYP1A2CYP2C9CYP2C19ALDH1A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | CYP1A2 4413/4885CYP2C9 4459/4885CYP2C19 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.